

Evaluation of T- and B-cell immunity after HPV vaccination by multi-colour EliSpot on a single cell level

Nicole Ettischer-Schmid¹ Kevin Strecker¹ Vivien Fritz¹ Andreas M. Kaufmann² Rosemarie Preyer¹ 1 Genome Identification Diagnostics GmbH (GenID), Straßberg, Germany 2 HPV Research Laboratory - Dept. for Gynecology - Charité - Universitätsmedizin Berlin - Campus Virchow Klinikum, Germany

Human papillomaviruses (HPV) are the causative agents for the great majority of anogenital and oropharyngeal cancers as well as anogenital warts. Vaccination against Human Papillomaviruses (HPV) with virus-like particles (VLPs) consisting vaccines is recommended in Germany for children from nine to fourteen years. The aim of this work was to evaluate mechanisms of the T- and B-cell mediated immunity and a putative cross-reactivity against L1-VLPs of the HPV-Types 6, 11, 16 and 18 by fluorescent Enzyme-Linked-ImmunoSpot (EliSpot) Assay.

To evaluate T-cell mediated immunity, IFNy, IL-2 and IL-5 were simultaneously detected in one well. Our hypothesis says, that fully vaccinated donors should express the most IFNy, whereas partly vaccinated donors should express less IFNy when stimulated with VLPs, in contrast to almost no IFNy expression in non-vaccinated donors. The individual T-cell reaction has been monitored to elucidate dynamic changes in T-cell patterns. Therefore, IFN-y (active response), IL-2 (memory response) and IL-5 (transient secretion during vaccination regime) were detected (Fig. 1). HPV specific B-cells were detected using fluorescently labeled VLPs from HPV types 6, 11, 16 and 18 to investigate potential cross-reactivity (Fig. 2).





Fig.2: Schematic drawing of the used AID B-Cell EliSpot. Numbers indicate the following: 1- plate with PVDF membrane for fluorescent applications; 2- coated antibodies; 3- secreted anti-HPV antibodies from B-cells; 4- antibody secreting Bcell. **6**- HPV6 VLPs, **11**- HPV11 VLPs , **16**- HPV16 VLPs and 18- HPV18 VLPs. B-cells were incubated o/n with fluorescently labeled VLPs. Secreted antibodies from donor bind to VLPs and are captured by the coated antibodies on the plate.

Fig. 1: Representative donors freshly vaccinated with Gardasil (left) and long-term vaccinated with Cervarix (right) from 3-colour Tcell EliSpot. Cells were stimulated with VLPs from HPV 6, 11, 16, 18 and a mixture of all (mix) at 3 μ g/ml.


cells only, PC = positive control, cells stimulated Pokeweed with Mitogen.


Shown here are the individual fluorescence channels: green- FITC-IFNy (left row), red-Cy3-IL-2 (middle row) and red-Cy5- IL-5 (left row). Pictures were obtained with an AID GmbH iSpot HPV 16 Spectrum Reader.



Gardasil

For HPV- reactive T-cells, this was proven with EliSpot assays and the groups were clearly distinguishable. Also, fully vaccinated donors showed the highest IL-2 expression. IL-5 expression was only detectable in vaccinated donors, which indicates functional T helper 2 T-cells against VLPs from HPV 11, 16 and 18 (Fig. 3). For evaluating functional B-cells, and cross-protection potential of the different vaccinations, VLPs from HPV 6&11 (low-risk-mix) and 16&18 (high-risk-mix) were labeled with different fluorescent dyes to evaluate B-cell numbers for both mixes in one well in parallel (Fig. 4). We were able to detect a dose-dependent spot number for all HPV types in vaccinated donors which were for all types higher than for non-vaccinated donors. B-cell reactions to the low-risk pool from patients exclusively vaccinated with high-risk strains could be observed. This indicates a cross-protective cellular immune reaction after vaccination.








Fig. 3: T-cell reactivity for IFNy after VLP-Mix (HPV 6, 11, 16, 18) stimulation. IFNy (A), IL-2 (B) and IL-5 (C) were detected in parallel in one well. For vaccinated donors (n=6), highly significant (IFN-y, IL-2) or significant (IL-5) T-cell reactions were detected, which was not the case in unvaccinated donors (n=15).

The range for effective vaccinations should be confirmed with more and well characterized donors. Furthermore, these trials could facilitate the detection of significant differences between vaccinated and non-vaccinated donors and open the possibility to define effectiveness of vaccination for cellular immune responses.




Fig 4: B-cell EliSpot of a vaccinated donor (3x Gardasil, last boost 2007) with fluorescently labelled HPV-VLPs. The particular figures successively represent the detected HPV-specific IgGs stimulated with VLP-Mix (A), HPV-11 (B),

HPV-6 (C), HPV-18 (D), HPV-16 (E) and the negative control (VLP-mix in media Without PBMCs) (F). The numbers indicate the spot counts and are obtained with the AID GmbH iSpot Spectrum Reader.



Cervarix